About PROACT

A multi-centre, prospective, randomised, open-label, blinded end-point, superiority trial to test the effectiveness of Enalapril (an ACE inhibitor) in preventing cardio-toxicity in patients with breast cancer undergoing anthracycline chemotherapy.

Full Title:                       Preventing cardiac damage in patients treated for breast cancer: a phase 3 Randomised, Open label, blinded endpoint, superiority trial of enalapril to prevent Anthracycline-induced CardioToxicity (PROACT).

Lay Title:                       PROACT: Can we prevent chemotherapy-related heart damage in patients with breast cancer?

Trial Identifiers:            

ClinTrials.gov: NCT03265574
EudraCT: 2017-001094-16
IRAS ID: 213348

Start date:                     

September 2017

End of recruitment:       

April 2019

Funder:                         

National Institute of Health Research – Research for Patient Benefit Programme (project reference PB-PG-0815-20061)

Chief Investigator:        

Dr David Austin
The James Cook University Hospital
South Tees Hospitals NHS Foundation Trust
Marton Road
Middlesbrough
TS4 3BW

Sponsor:                       

South Tees Hospitals NHS Foundation Trust

Clinical Trials Unit:       

Newcastle Clinical Trials Unit, Newcastle University
Tel: 01642 854 638
Email: nctu.tees@newcastle.ac.uk